Ulcerative ColitisPhase 2NCT05177835
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
A Phase 2 study testing ABX464 in people with Ulcerative Colitis, run by Abivax S.A. at 46 sites in 14 countries.
Trial summary
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ulcerative Colitis
- What is being tested?
- ABX464
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 203 participants
- Where
- 46 sitesin 14 countries
- Study dates
- 3 Dec 2021to Apr 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies
- Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of ≤1 ;
- Subjects able and willing to comply with study visits and procedures;
- Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures;
- 5. Women of childbearing potential and men receiving the study treatment and their partners must agree to continue a highly effective contraceptive method during the study and for 6 months (180 days) after end of study or early termination. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male subjects must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male subjects should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male subjects must not donate sperm as long as contraception is required. For the purpose of this protocol, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. Finally, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy;
- Subjects should be affiliated to a social security regimen (for French sites only).
Who cannot join
- Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study
- Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
- Subjects who are participating or plan to participate in other investigational studies (other than induction study) during the study.
Trial locations and contacts
46 sites in 14 countries.
46 sites in 14 countries
Poland13 sites
Centrum Medyczne Plejady
Krakow
Samodzielny PZOZ w Lecznej
Łęczna, 21-010
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj sp. p
Lublin
Wojskowy Szpital Kliniczny w Lublinie
Lublin
Medicome Sp. z o. o.
Oświęcim
Trialmed CRS
Piotrkow Trybunalski
Termedia Sp. z o.o (NSZOZ Termedica - Centrum Badan Klinicznych)
Poznan
Ośrodek Badań Klinicznych "METABOLICA"
Tarnów
Medical Network Sp. z o.o.
Warsaw
Santa Sp. z o.o.
Warsaw
Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw
Centrum Medyczne Oporow
Wroclaw
LexMedica
Wroclaw
France5 sites
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble
Centre Hospitalier Universitaire De Montpellier
Montpellier
CHU Nantes - Hôtel Dieu
Nantes
Institut des MICI
Neuilly-sur-Seine
CHU Saint Etienne - Hôpital Nord
Saint-Etienne
Hungary4 sites
DRC Gyogyszervizsgalo Kozpont Kft.
Balatonfüred
Semmelweis University
Budapest
Vasutegeszseguegyi Nonprofit Koezhasznu Kft.
Debrecen
Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház I. Belgyógyászat
Győr
Germany3 sites
Goethe University Frankfurt
Frankfurt
Studiengesellschaft BSF UG (haftungsbeschraenkt)
Halle
Medizinische Hochschule Hannover
Hanover
Italy3 sites
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma
Humanitas Mirasole S.p.A.
Rozzano
IRCCS Ospedale Sacro Cuore Don Calabria
Verona
Slovakia3 sites
Cliniq s.r.o.
Bratislava
GASTRO I, s.r.o.
Prešov
Endomed s.r.o
Vranov nad Topľou
Slovenia3 sites
Splošna bolnišnica Celje
Celje
Univerzitetni klinični center Maribor
Maribor
Splosna Bolnisnica Murska Sobota
Murska Sobota
Austria2 sites
Medizinische Universitaet Innsbruck
Innsbruck
Medical University of Vienna
Vienna
Serbia2 sites
Kliničko bolnički centar Zvezdara
Belgrade
Opšta bolnica "Đorđe Joanović" Zrenjanin Odsek za gastroenterologiju
Zrenjanin
Ukraine2 sites
Communal non-commercial enterprise "Cherkasy Regional Hospital of Cherkasy regional council"
Cherkasy
Communal non-commercial enterprise "Khmelnytska Regional Hospital" of Khmelnytskiy regional council
Khmelnytskyi
About this study
Official title: A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment.
All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement.
Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.
- Conditions
- Ulcerative Colitis
- Being tested
- ABX464
- Keywords
- Moderate to severe ulcerative colitis
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ABX464Drug
All subjects will receive ABX464 given at 25 mg QD.
| Study group | Role | What they receive |
|---|---|---|
| ABX464 -25mg | Experimental | All subjects will receive ABX464 given at 25 mg QD. Receives: Drug: ABX464 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of adverse events in ABX464 treated subjects
To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.
Measured: From Baseline to a maximum period of 78 months
Secondary outcomes (4)
Percentage of subjects reaching clinical remission at yearly visits.
To evaluate the long-term effect of ABX464 on clinical remission
Measured: From Baseline to a maximum period of 78 months
Percentage of subjects reaching endoscopic remission at yearly visits
To evaluate the long-term effect of ABX464 on endoscopic remission
Measured: From Baseline to a maximum period of 78 months
Percentage of subjects reaching clinical response at yearly visits
To evaluate the long-term effect of ABX464 on clinical response
Measured: From Baseline to a maximum period of 78 months
Percentage of subjects reaching endoscopic improvement at yearly visits
To evaluate the long-term effect of ABX464 on endoscopic improvement
Measured: From Baseline to a maximum period of 78 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2022
- Study start3 Dec 2021
- Primary completionMar 2028 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Open Label Follow-up Study
- Masking
- None (open label)
- Enrolment
- 203 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abivax S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bram Verstockt, MD, Principal investigator, Universitaire Ziekenhuizen KU Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05177835
- Sponsor's protocol ID
- ABX464-108
- Status last verified
- Apr 2026
- First submitted
- 15 Dec 2021
- Last updated
- 27 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis
- ClinicalTrials.gov ID
- NCT05177835
- Acronym / sponsor ID
- ABX464-108
- Conditions
- Ulcerative Colitis
- Keywords
- Moderate to severe ulcerative colitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 203 participants (estimated)
- Lead sponsor
- Abivax S.A.Industry (pharma, biotech, devices)
- Study start
- 3 Dec 2021 (actual)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 5 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment.
All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement.
Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Open Label Follow-up Study
| Arm | Type | Receives |
|---|---|---|
| ABX464 -25mg | Experimental | Drug: ABX464All subjects will receive ABX464 given at 25 mg QD. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies
- Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of ≤1 ;
- Subjects able and willing to comply with study visits and procedures;
- Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures;
- 5. Women of childbearing potential and men receiving the study treatment and their partners must agree to continue a highly effective contraceptive method during the study and for 6 months (180 days) after end of study or early termination. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male subjects must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male subjects should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male subjects must not donate sperm as long as contraception is required. For the purpose of this protocol, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. Finally, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy;
Key exclusion criteria (3 listed)
- Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study
- Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
- Subjects who are participating or plan to participate in other investigational studies (other than induction study) during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ABX464All subjects will receive ABX464 given at 25 mg QD. | Drug | ABX464 -25mg |
Primary outcome
Number of adverse events in ABX464 treated subjects
Time frame: From Baseline to a maximum period of 78 months
To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.
4 secondary outcomes
Percentage of subjects reaching clinical remission at yearly visits.
Time frame: From Baseline to a maximum period of 78 months
Percentage of subjects reaching endoscopic remission at yearly visits
Time frame: From Baseline to a maximum period of 78 months
Percentage of subjects reaching clinical response at yearly visits
Time frame: From Baseline to a maximum period of 78 months
Percentage of subjects reaching endoscopic improvement at yearly visits
Time frame: From Baseline to a maximum period of 78 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Ulcerative Colitis
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bram Verstockt, MD principal investigator
Universitaire Ziekenhuizen KU Leuven
46 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ABX464 in people with Ulcerative Colitis, run by Abivax S.A. at 46 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 46 sites in Poland, France, Hungary, Germany, Italy and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of adverse events in ABX464 treated subjects (time frame: From Baseline to a maximum period of 78 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026.